Approaches to M&As in pharma points to each company’s philosophy
Deal or no deal
Related Posts
Study reveals genetic mutations associated with aggressive prostate cancer
Aggressive prostate cancer accounts for up to 15% of all prostate cancer diagnoses Scientists from the Institute of Cancer Research (ICR) have revealed new inherited […]
Bee Koen Low – PharmaTimes
Kelso Pharma has appointed Bee Koen Low as Chief Operating Officer Kelso Pharma has announced the appointment of Bee Koen Low as its first Chief […]